![Nigel McCracken](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nigel McCracken
Direttore operativo presso
VIRAX BIOLABS GROUP LIMITED
Patrimonio netto: 7 447 $ in data 30/06/2026
Profilo
Nigel McCracken currently works at Virax Biolabs Group Ltd., as Chief Operating Officer & Director.
Dr. McCracken also formerly worked at Debiopharm International SA, as Executive Director & VP-Translational Medicine from 2014 to 2019, NuCana Plc, as COO, Senior VP-Discovery & Early Development, and BerGenBio ASA, as Chief Scientific Officer from 2021 to 2023.
Dr. McCracken received his undergraduate degree from the University of Strathclyde and graduate degree from King's College London.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 02/07/2026 | 2.533 ( 0,32% ) | 7 447 $ | 30/06/2026 |
Posizioni attive di Nigel McCracken
| Società | Posizione | Inizio |
|---|---|---|
| VIRAX BIOLABS GROUP LIMITED | Direttore operativo | 01/09/2023 |
Precedenti posizioni note di Nigel McCracken
| Società | Posizione | Fine |
|---|---|---|
| ONCOINVENT ASA | Direttore Tecnico/Scientifico/R&S | 01/09/2023 |
Debiopharm International SA
 Debiopharm International SA BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops drugs to cure cancer and infectious diseases | Direttore/Membro del Consiglio | 01/04/2019 |
| NUCANA PLC | Direttore operativo | - |
Formazione di Nigel McCracken
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
5
Relazioni di 1° grado
6
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 6 |
|---|---|
Debiopharm International SA
Debiopharm International SA BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops drugs to cure cancer and infectious diseases | Health Technology |
University of Strathclyde
 University of Strathclyde Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
King's College London
 King's College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BerGenBio ASA
 BerGenBio ASA Pharmaceuticals: MajorHealth Technology Develops drugs for aggressive, drug resistant cancers | Health Technology |
NuCana Plc
 NuCana Plc BiotechnologyHealth Technology Develops and commercializes novel anti-cancer medicines | Health Technology |
Virax Biolabs Group Ltd.
 Virax Biolabs Group Ltd. Financial ConglomeratesFinance Develops and distributes immunology software, platform and medical devices | Finance |
